Your browser is no longer supported. Please, upgrade your browser.
DBV Technologies S.A.
Index- P/E- EPS (ttm)-1.13 Insider Own0.40% Shs Outstand109.97M Perf Week-4.85%
Market Cap172.65M Forward P/E- EPS next Y-1.73 Insider Trans0.00% Shs Float61.29M Perf Month12.95%
Income- PEG- EPS next Q-0.54 Inst Own33.13% Short Float2.61% Perf Quarter-71.86%
Sales1.56M P/S110.39 EPS this Y-65.10% Inst Trans- Short Ratio2.33 Perf Half Y-70.71%
Book/sh1.06 P/B1.48 EPS next Y16.80% ROA- Target Price7.00 Perf Year-73.52%
Cash/sh- P/C- EPS next 5Y21.22% ROE- 52W Range1.35 - 6.88 Perf YTD-1.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.18% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low16.21% ATR0.12
Employees92 Current Ratio- Sales Q/Q-68.20% Oper. Margin- RSI (14)29.61 Volatility3.50% 3.83%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close1.60
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume685.60K Price1.57
Recom2.00 SMA20-5.68% SMA50-34.03% SMA200-66.03% Volume62,530 Change-1.87%
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Dec-16-19Initiated Citigroup Buy
Sep-05-19Resumed Morgan Stanley Equal-Weight
Jun-17-19Initiated Goldman Buy
Dec-20-18Downgrade Stifel Buy → Hold
Dec-20-18Downgrade Jefferies Buy → Hold
Dec-20-18Downgrade BofA/Merrill Buy → Underperform
Dec-20-18Downgrade Barclays Overweight → Equal Weight
Oct-31-17Upgrade Societe Generale Sell → Hold
Oct-24-17Downgrade Societe Generale Buy → Sell
Oct-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-23-17Initiated Deutsche Bank Buy $46
Mar-16-17Upgrade Societe Generale Hold → Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Jan-21-22 04:30PM  
Jan-18-22 05:38PM  
Jan-12-22 04:30PM  
Jan-07-22 01:30AM  
Dec-20-21 04:15PM  
Dec-10-21 04:30PM  
Nov-24-21 01:30AM  
Nov-04-21 04:30PM  
Nov-01-21 03:34PM  
Oct-29-21 05:07PM  
Oct-27-21 03:35PM  
Oct-26-21 04:15PM  
Oct-12-21 04:30PM  
Sep-08-21 04:00PM  
Aug-31-21 01:30AM  
Aug-20-21 04:15PM  
Aug-09-21 04:30PM  
Aug-06-21 04:30PM  
Aug-02-21 04:15PM  
Jul-26-21 04:30PM  
Jul-07-21 04:30PM  
Jun-15-21 04:30PM  
Jun-02-21 01:30AM  
May-19-21 04:30PM  
May-17-21 04:30PM  
May-05-21 05:00PM  
May-03-21 01:30AM  
Apr-29-21 01:30AM  
Apr-28-21 04:30PM  
Apr-02-21 04:30PM  
Apr-01-21 06:30PM  
Mar-26-21 04:30PM  
Mar-17-21 06:30PM  
Mar-12-21 04:30PM  
Mar-11-21 04:30PM  
Mar-05-21 04:30PM  
Mar-03-21 06:00PM  
Mar-01-21 01:30AM  
Feb-24-21 01:30AM  
Feb-22-21 01:30AM  
Feb-19-21 01:30AM  
Feb-11-21 04:30PM  
Jan-29-21 04:30PM  
Jan-15-21 11:23AM  
Jan-14-21 04:30PM  
Jan-07-21 01:30AM  
Jan-05-21 04:30PM  
Dec-15-20 04:30PM  
Dec-01-20 11:50AM  
Nov-24-20 01:30AM  
Nov-11-20 04:30AM  
Nov-10-20 01:30AM  
Nov-09-20 01:30AM  
Nov-02-20 11:50AM  
Oct-30-20 02:30AM  
Oct-08-20 04:01PM  
Sep-15-20 04:30PM  
Sep-09-20 01:30AM  
Sep-02-20 04:30PM  
Aug-12-20 04:01PM  
Aug-11-20 10:59AM  
Aug-05-20 08:17AM  
Aug-04-20 05:09PM  
Jul-31-20 01:30AM  
Jul-20-20 04:01PM  
Jul-15-20 04:01PM  
Jul-10-20 09:00AM  
Jul-07-20 09:30PM  
Jun-26-20 08:28AM  
Jun-11-20 04:01PM  
Jun-04-20 04:30PM  
Jun-02-20 04:30PM  
May-12-20 04:01PM  
Apr-30-20 04:01PM  
Apr-20-20 04:01PM  
Apr-15-20 06:00AM  
Apr-10-20 04:01PM  
Mar-31-20 03:46AM  
Mar-30-20 04:01PM  
Mar-26-20 11:00AM  
Mar-20-20 04:15PM  
Mar-17-20 04:00PM  
Mar-16-20 04:30PM  
Mar-09-20 02:58AM  
Mar-05-20 11:09AM  
Mar-04-20 04:30PM  
Mar-02-20 01:30AM  
Feb-24-20 04:00PM  
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestle Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.